Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

Similar articles for PubMed (Select 20228781)

1.

HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma.

Mahajan A, Liu Z, Gellert L, Zou X, Yang G, Lee P, Yang X, Wei JJ.

Mod Pathol. 2010 May;23(5):673-81. doi: 10.1038/modpathol.2010.49. Epub 2010 Mar 12.

2.

[Overexpression of high mobility group A2 and its correlation with microRNA let-7 family in serous ovarian cancers].

Yang J, Zhang Q, Dong JQ, Chang XH, He XJ.

Beijing Da Xue Xue Bao. 2012 Oct 18;44(5):749-54. Chinese.

3.

Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.

McMillen BD, Aponte MM, Liu Z, Helenowski IB, Scholtens DM, Buttin BM, Wei JJ.

Mod Pathol. 2012 Dec;25(12):1644-53. doi: 10.1038/modpathol.2012.118. Epub 2012 Jul 13.

4.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760
5.

HMGA2 and high-grade serous ovarian carcinoma.

Wu J, Wei JJ.

J Mol Med (Berl). 2013 Oct;91(10):1155-65. doi: 10.1007/s00109-013-1055-8. Epub 2013 May 19. Review.

PMID:
23686260
6.

Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma.

Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P, Wei JJ.

Mol Cancer Res. 2008 Apr;6(4):663-73. doi: 10.1158/1541-7786.MCR-07-0370.

7.

HMGA2: a potential biomarker complement to P53 for detection of early-stage high-grade papillary serous carcinoma in fallopian tubes.

Wei JJ, Wu J, Luan C, Yeldandi A, Lee P, Keh P, Liu J.

Am J Surg Pathol. 2010 Jan;34(1):18-26. doi: 10.1097/PAS.0b013e3181be5d72.

PMID:
19898227
8.
9.

HMGA2 gene is a promising target for ovarian cancer silencing therapy.

Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa O.

Int J Cancer. 2008 Jul 15;123(2):348-56. doi: 10.1002/ijc.23491.

PMID:
18452175
10.

Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.

Chien J, Fan JB, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC.

Gynecol Oncol. 2009 Jul;114(1):3-11. doi: 10.1016/j.ygyno.2009.04.002. Epub 2009 May 1.

PMID:
19410283
11.

Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.

Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG.

Int J Gynecol Pathol. 2007 Jul;26(3):328-33.

PMID:
17581420
12.

Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.

Têtu B, Popa I, Bairati I, L'Esperance S, Bachvarova M, Plante M, Harel F, Bachvarov D.

Mod Pathol. 2008 Aug;21(8):1002-10. doi: 10.1038/modpathol.2008.80. Epub 2008 May 23.

13.

HMGA2 overexpression in non-small cell lung cancer.

Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J.

Mol Carcinog. 2007 Jul;46(7):503-11.

PMID:
17477356
14.
15.

Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors.

Buchynska LG, Nesina IP, Yurchenko NP, Bilyk OO, Grinkevych VN, Svintitsky VS.

Exp Oncol. 2007 Mar;29(1):49-53.

PMID:
17431389
16.

Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma.

Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET.

Mol Carcinog. 2003 Feb;36(2):53-9.

PMID:
12557260
17.

miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.

Kim TH, Song JY, Park H, Jeong JY, Kwon AY, Heo JH, Kang H, Kim G, An HJ.

Cancer Lett. 2015 Jan 28;356(2 Pt B):937-45. doi: 10.1016/j.canlet.2014.11.011. Epub 2014 Nov 10.

PMID:
25444913
18.

HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B.

Virchows Arch. 2012 May;460(5):505-13. doi: 10.1007/s00428-012-1228-9. Epub 2012 Apr 4.

PMID:
22476403
19.

HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes.

Wu J, Liu Z, Shao C, Gong Y, Hernando E, Lee P, Narita M, Muller W, Liu J, Wei JJ.

Cancer Res. 2011 Jan 15;71(2):349-59. doi: 10.1158/0008-5472.CAN-10-2550. Epub 2011 Jan 11.

20.

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

Köbel M, Reuss A, Bois Ad, Kommoss S, Kommoss F, Gao D, Kalloger SE, Huntsman DG, Gilks CB.

J Pathol. 2010 Oct;222(2):191-8. doi: 10.1002/path.2744.

PMID:
20629008
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk